Briefing
Early Detection of Metastatic Relapse and Monitoring of Therapeutic Efficacy by Ultra-Deep Sequencing of Plasma Cell-Free DNA in Patients With Urothelial Bladder Carcinoma.
ctDNA at diagnosis HR 29.1, P=0.001.
- n: 68 patients, 656 plasma samples
- Assay: Tumor-informed ultra-deep sequencing (median 105,000x)